Filtered By:
Specialty: Cardiology
Condition: Bleeding
Countries: Netherlands Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 29 results found since Jan 2013.

Real-life use of Rivaroxaban in the Netherlands: data from the  Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
CONCLUSION: In the Dutch subset of the XANTUS registry, we observed low rates of major bleeding and label-discordant dosing and high persistence rates during one year of follow-up in patients receiving rivaroxaban in routine clinical practice. However, documenting the motivation of novel oral anticoagulant (NOAC) type and dose is essential to study label-discordant prescription, a potential safety paradox and identify patient characteristics to optimise NOAC use and adherence. PMID: 28674871 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - July 3, 2017 Category: Cardiology Authors: Pisters R, van Vugt SPG, Brouwer MA, Elvan A, Ten Holt WL, Zwart PAG, Kirchhof P, Crijns HJGM, Hemels MEW Tags: Neth Heart J Source Type: research

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation.
CONCLUSIONS: Percutaneous LAAC may provide an alternative strategy to long-term OAC therapy in AF patients with a high bleeding risk. During follow-up, both ischaemic stroke and recurrent bleeding rates were lower than expected based on the CHA2DS2-VASc and HAS-BLED scores respectively. PMID: 31187455 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - June 10, 2019 Category: Cardiology Authors: Wintgens LIS, Vorselaars VMM, Klaver MN, Swaans MJ, Alipour A, Rensing BJWM, Post MC, Boersma LVA Tags: Neth Heart J Source Type: research

Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a  meta-analysis of randomised trials.
CONCLUSIONS: Short DAPT following DES implantation results in a significant reduction of major bleeding events with no apparent increase in all-cause death, myocardial infarction, stent thrombosis, or stroke. Future dedicated trials should investigate the optimal strategies for patient-tailored DAPT in various subgroups. PMID: 29541996 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - March 14, 2018 Category: Cardiology Authors: Rozemeijer R, Voskuil M, Greving JP, Bots ML, Doevendans PA, Stella PR Tags: Neth Heart J Source Type: research

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a  dedicated NOAC clinic.
CONCLUSIONS: We observed low rates of bleeding and adverse drug reactions. However, rates of mortality and discontinuation were relatively high. These results could possibly be explained by the real-world nature of the data including higher-risk patients. PMID: 31773474 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - November 25, 2019 Category: Cardiology Authors: de Veer AJWM, Bennaghmouch N, Wijffels MCEF, Ten Berg JM Tags: Neth Heart J Source Type: research

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research

Design and rationale of ischaemia-driven complete revascularisation versus usual care in patients with non-ST-elevation myocardial infarction and multivessel coronary disease: the South Limburg Myocardial Infarction (SLIM) trial.
CONCLUSION: The SLIM trial aims to provide evidence whether FFR-guided complete revascularisation by PCI is superior to usual care with respect to clinical outcomes (major adverse cardiovascular events) in non-STEMI patients with MVD. PMID: 31531823 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - September 16, 2019 Category: Cardiology Authors: Pustjens TFS, Streukens B, Vainer J, Gho B, Ruiters AW, Stein M, Ilhan M, Veenstra L, Theunissen R, Bekkers SCAM, Van't Hof AWJ, Rasoul S Tags: Neth Heart J Source Type: research

Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020.
Abstract In recent years, as more and more experience has been gained with prescribing direct oral anticoagulants (DOACs), new research initiatives have emerged in the Netherlands to improve the safety and appropriateness of DOAC treatment for stroke prevention in patients with atrial fibrillation (AF). These initiatives address several contemporary unresolved issues, such as inappropriate dosing, non-adherence and the long-term management of DOAC treatment. Dutch initiatives have also contributed to the development and improvement of risk prediction models. Although fewer bleeding complications (notably intracran...
Source: Netherlands Heart Journal - July 31, 2020 Category: Cardiology Authors: Chu G, Seelig J, Trinks-Roerdink EM, Geersing GJ, Rutten FH, de Groot JR, Huisman MV, Hemels MEW Tags: Neth Heart J Source Type: research

Major threats to early safety after transcatheter aortic valve implantation in a  contemporary cohort of real-world patients
CONCLUSION: A variety of underlying mechanisms and causes form a wide spectrum of major threats affecting early safety in 11.7% of patients undergoing TAVI in a contemporary cohort of real-world patients.PMID:34724147 | DOI:10.1007/s12471-021-01638-8
Source: Netherlands Heart Journal - November 1, 2021 Category: Cardiology Authors: D J van Ginkel J Brouwer N D van Hemert A O Kraaijeveld B J W M Rensing M J Swaans L Timmers M Voskuil P R Stella J M Ten Berg Source Type: research

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation  (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.
This study provides insight into the changes these new drugs will bring about in Dutch clinical practice.GARFIELD-AF is a large-scale observational AF patient registry initiated in 2009 to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF in particular. The registry includes a wide array of baseline characteristics and has a particular focus on: (1) bleeding and thromboembolic events; (2) international normalised ratio fluctuations; and (3) therapy compliance and persistence patterns. The results in this paper provide the baseline characteristics of the first cohorts of D...
Source: Netherlands Heart Journal - August 24, 2016 Category: Cardiology Authors: Ten Cate V, Ten Cate H, Verheugt FW Tags: Neth Heart J Source Type: research

Mitro-aortic pathology: a  point of view for a fully transcatheter staged approach.
Mitro-aortic pathology: a point of view for a fully transcatheter staged approach. Neth Heart J. 2017 Aug 02;: Authors: D'Ancona G, Paranskaya L, Öner A, Kische S, Ince H Abstract Severe aortic valve stenosis (AVS) and mitral valve regurgitation (MVR) often coexist. Although a fully percutaneous treatment for the two conditions, by means of transcatheter aortic valve implantation (TAVI) followed by MitraClip, can be appealing in selected high-risk candidates, critical and strategical reasoning should be applied. In a 3-year period we have developed a single-centre experience of 14 patients who ...
Source: Netherlands Heart Journal - August 2, 2017 Category: Cardiology Authors: D'Ancona G, Paranskaya L, Öner A, Kische S, Ince H Tags: Neth Heart J Source Type: research

Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
Abstract Patients with atrial fibrillation who undergo a coronary intervention are eligible for both anticoagulation and (dual) antiplatelet therapy ((D)APT). An optimal balance has to be found to reduce the thromboembolic risk (i.e. stroke, systemic embolism and myocardial infarction) and to minimise the increased risk of bleeding with concomitant use of an anticoagulant and (D)APT. Owing to a lack of evidence, the guideline recommendations are predominantly based on expert opinion. Current evidence indicates that the combination of a non-vitamin K oral anticoagulant (NOAC) and clopidogrel is safer than vitam...
Source: Netherlands Heart Journal - May 8, 2018 Category: Cardiology Authors: Jacobs MS, Tieleman RG Tags: Neth Heart J Source Type: research

One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmond collective cardiology research study.
CONCLUSIONS: In routine practice, a tailored approach of prasugrel prescription in ACS patients undergoing PCI, resulted in low ischaemic and low bleeding rates up to 1 year post PCI. PMID: 29931649 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - June 21, 2018 Category: Cardiology Authors: Yetgin T, Boersma E, Smits PC, de Vries AG, Huijskens E, Zijlstra F, van der Linden MMJM, van Geuns RJM, CCR Study Investigators Tags: Neth Heart J Source Type: research

Frailty score for elderly patients is associated with short-term clinical outcomes in patients with ST-segment elevated myocardial infarction treated with primary percutaneous coronary intervention.
CONCLUSIONS: VMS score for frailty is independently associated with short-term mortality and PCI-related SAE in elderly patients with STEMI treated with primary PCI. These results suggest that frailty in elderly patients is an important feature to measure and to be taken into account when developing risk models. PMID: 30771094 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - February 15, 2019 Category: Cardiology Authors: Hermans MPJ, Eindhoven DC, van Winden LAM, de Grooth GJ, Blauw GJ, Muller M, Schalij MJ Tags: Neth Heart J Source Type: research

Outcome of mechanical circulatory support at the University Medical Centre Utrecht.
CONCLUSION: Not only short-term results but also 5‑year survival after cf-LVAD support demonstrate that MCS is a promising therapy as an extended bridge to heart transplantation. However, the incidence of several major complications still has to be addressed. PMID: 32096095 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - February 23, 2020 Category: Cardiology Authors: Felix SEA, Ramjankhan FZ, Buijsrogge MP, Jacob KA, Asselbergs FW, Oerlemans MIF, Kirkels JH, van Laake LW, Oppelaar AMC, Suyker WJL, de Jonge N Tags: Neth Heart J Source Type: research